Establishment Labs (NASDAQ:ESTA) Share Price Breaks Above 50-Day Moving Average – Time to Sell?

Establishment Labs Holdings Inc. (NASDAQ:ESTA)’s stock price crossed above its 50 day moving average during trading on Friday. The stock has a 50 day moving average of $66.26 and traded as high as $67.98. Establishment Labs shares last traded at $67.02, with a volume of 321,678 shares changing hands.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on the company. BTIG Research lowered their price target on Establishment Labs from $103.00 to $93.00 and set a “buy” rating for the company in a research report on Thursday, October 29th. Needham & Company LLC increased their price objective on shares of Establishment Labs from $86.00 to $95.00 and gave the company a “buy” rating in a research report on Thursday, August 6th. Weiss Ratings restated a “sell (e+)” rating on shares of Establishment Labs in a research note on Monday, September 21st. Citigroup upgraded shares of Establishment Labs from a “neutral” rating to a “buy” rating and set a $92.00 price objective for the company in a research note on Thursday, August 13th. Finally, Stifel Nicolaus began coverage on shares of Establishment Labs in a report on Wednesday, October 14th. They issued a “buy” rating and a $85.00 target price for the company. Nine investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $95.00.

Establishment Labs Price Performance

The company has a debt-to-equity ratio of 12.11, a current ratio of 3.84 and a quick ratio of 2.52. The company has a market capitalization of $2.00 billion, a PE ratio of -52.36 and a beta of 1.03. The firm has a 50-day moving average of $66.26 and a 200 day moving average of $72.30.

Establishment Labs (NASDAQ:ESTA) last released its quarterly earnings data on Friday, October 30th. The company reported ($0.35) EPS for the quarter, missing the consensus estimate of ($0.26) by ($0.09). The business had revenue of $71.99 million during the quarter, compared to the consensus estimate of $66.81 million. Establishment Labs had a negative return on equity of 185.60% and a negative net margin of 14.56%. Establishment Labs’s quarterly revenue was up 33.8% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.38) earnings per share. As a group, research analysts anticipate that Establishment Labs Holdings Inc. will post -1.18 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the stock. CenterBook Partners LP grew its stake in shares of Establishment Labs by 123.9% during the 3rd quarter. CenterBook Partners LP now owns 9,033 shares of the company’s stock valued at $580,000 after purchasing an additional 4,999 shares during the period. State of Wyoming lifted its stake in shares of Establishment Labs by 102.1% in the 3rd quarter. State of Wyoming now owns 2,057 shares of the company’s stock worth $132,000 after purchasing an additional 1,039 shares during the period. China Universal Asset Management Co. Ltd. lifted its stake in shares of Establishment Labs by 220.0% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 2,560 shares of the company’s stock worth $163,000 after purchasing an additional 1,760 shares during the period. Sterling Capital Management LLC lifted its stake in shares of Establishment Labs by 849.5% in the 3rd quarter. Sterling Capital Management LLC now owns 902 shares of the company’s stock worth $58,000 after purchasing an additional 807 shares during the period. Finally, State of Alaska Department of Revenue purchased a new position in shares of Establishment Labs in the third quarter worth approximately $80,000. 72.91% of the stock is owned by hedge funds and other institutional investors.

Establishment Labs Company Profile

Establishment Labs Holdings Inc is a medical technology company focused on women’s health and the breast aesthetics market. The company develops, manufactures and commercializes breast implants and related technologies designed for breast augmentation, reconstruction and revision procedures.

Its product portfolio includes the Motiva line of breast implants, which incorporates the company’s proprietary implant materials, surface technologies and design features. Establishment Labs also offers Motiva Flora tissue expanders for use in breast reconstruction and has developed Mia Femtech, a minimally invasive breast enhancement procedure intended to provide a less invasive alternative to traditional augmentation techniques.

Founded in 2004, Establishment Labs is headquartered in Costa Rica and serves physicians, hospitals and patients in international markets.